Evidence map›Paper›PMID 35527147›Full record

ReviewBiomaterials advances2022

The feasibility of injectable PRF (I-PRF) for bone tissue engineering and its application in oral and maxillofacial reconstruction: From bench to chairside.

Nima Farshidfar, Mohammad Amin Amiri, Dana Jafarpour, Shahram Hamedani, Seyyed Vahid Niknezhad, Lobat Tayebi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomaterials advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. [Evaluation of the clinical effect of concentrated growth factor combined with sticky bone in maxillary anterior alveolar ridge preservation].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2025
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nima FarshidfarOrthodontic Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: n_farshidfar@sums.ac.ir.
Mohammad Amin AmiriStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Dana JafarpourFaculty of Dentistry, McGill University, Montreal, Canada.
Shahram HamedaniOral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyyed Vahid NiknezhadBurn and Wound Healing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Lobat TayebiMarquette University School of Dentistry, Milwaukee, WI, USA. Electronic address: lobat.tayebi@marquette.edu.

Funding

Supplement: Development of an Integrated 3D Human Osteo-Mucosal ModelR15DE027533 · NIDCR · MARQUETTE UNIVERSITY · PI TAYEBI, LOBAT · 2018 to 2021
$816k
Vascularization of critical-sized craniomaxillofacial defectsR56DE029191 · NIDCR · MARQUETTE UNIVERSITY · PI TAYEBI, LOBAT · 2021 to 2021
$363k
NIDCR NIH HHS R15 DE027533NIDCR NIH HHS R56 DE029191
6 · The paper itself

Abstract

Among all the biomaterials introduced in the field of bone tissue engineering, injectable platelet-rich fibrin (I-PRF) has recently gained considerable attention. I-PRF, as a rich source of biologically active molecules, is a potential candidate which can be easily obtained in bedside and constitutes several biological factors which can result in higher anti-bacterial, anti-inflammatory and regenerative capabilities. According to the studies evaluating the osteogenic efficacy of I-PRF, this biomaterial has exhibited favorable outcomes in terms of adhesion, differentiation, migration, proliferation and mineralization potential of stem cells. In addition, the injectability and ease-of-applicability of this biomaterial has led to its various clinical applications in the oral and maxillofacial bone regeneration such as ridge augmentation, sinus floor elevation, cleft palate reconstruction and so on. Furthermore, to enhance the clinical performance of I-PRF, albumin gel-PRF as a long-lasting material for long-term utilization has been recently introduced with a gradual increase in growth factor release pattern. This review provides a comprehensive approach to better evaluate the applicability of I-PRF by separately appraising its performance in in-vitro, in-vivo and clinical situations. The critical approach of this review toward the different production protocols and different physical and biological aspects of I-PRF can pave the way for future studies to better assess the efficacy of I-PRF in bone regeneration.

Indexed as

Platelet-Rich FibrinSinus Floor AugmentationBiocompatible MaterialsFeasibility StudiesTissue EngineeringBiocompatible MaterialsBiomaterialBone regenerationI-PRFOral surgeryPlatelet rich fibrinTissue engineering

Identifiers

PMID35527147
PMCPMC9295636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.